I am in total agreement Turbo.
My comments re a DCF valuation are connected to your line of thought.
We may not have enough ammo to achieve a DCF valued takeover at present (multiple times current SP). As the progression of P3 trial design, undisclosed in vitro conditions tested, and even initiation of a P3 unfolds, could cause substantial SP appreciation and result in a T/O nearer to a fair DCF valuation.
I am in total agreement Turbo.My comments re a DCF valuation are...
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.13 |
Change
-0.010(0.07%) |
Mkt cap ! $1.933B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $15.30 | $14.96 | $6.401M | 422.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1 | $15.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.16 | 6015 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |